Company Encyclopedia
View More
name
ESSEX BIO-TECH
01061.HK
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally. The company operates through Ophthalmology, Surgical, and Provision of services segments. It researches and develops therapeutic fibroblast growth factor products to treat cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, eye gel, and unit-dose eye drops to treat ocular wounds; and Tobramycin, Levofloxacin, Sodium Hyaluronate, Diquafosol Sodium, and Moxifloxacin Hydrochloride eye drops, as well as Iodized lecithin capsules.
1.377 T
01061.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking8/52
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE14.60%A
    • Profit Margin18.23%A
    • Gross Margin88.83%A
  • Growth ScoreC
    • Revenue YoY3.10%C
    • Net Profit YoY19.13%B
    • Total Assets YoY9.04%B
    • Net Assets YoY12.82%B
  • Cash ScoreC
    • Cash Flow Margin548.50%C
    • OCF YoY3.10%C
  • Operating ScoreC
    • Turnover0.55C
  • Debt ScoreB
    • Gearing Ratio29.68%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ESSEX BIO-TECH released its interim results, with a profit of HKD 163 million during the period, an increase of 3.79% year-on-year

    According to the Zhitong Finance APP, ESSEX BIO-TECH announced its interim results for the six months ending June 30, 2025, with a revenue of HKD 877 million, an increase of 5.79% year-on-year; the profit for the period was HKD 163 million, an increase of 3.79% year-on-year; the basic earnings per share were HKD 0.2882; and it proposed an interim dividend of HKD 0.07 per share

    Zhitong·
    HK
    01061
    -2.21%
    Zhitong·
    HK
    01061
    -2.21%

    ESSEX BIO-TECH: The biological product license application for the anti-VEGF ophthalmic injection (HLX04-O) for the treatment of wet AMD has been accepted

    ESSEX BIO-TECH announced that its biologics license application for the anti-VEGF ophthalmic injection biologic (HLX04-O) for the treatment of wet AMD has been accepted by the National Medical Products Administration of China. This product is co-developed by the company's wholly-owned subsidiary and HENLIUS, optimized based on HENLIUS's Hanbeitai, aiming to meet the needs of ophthalmic medications. The Phase III clinical study of HLX04-O is being conducted in China and several other countries, with completion expected in 2025

    Zhitong·
    HK
    02696
    +0.15%
    HK
    01061
    -2.21%
    Zhitong·
    HK
    02696
    +0.15%
    HK
    01061
    -2.21%

    ESSEX BIO-TECH's subsidiary has been approved for the commercialization of multi-dose sodium dequalinium eye drops in China

    According to the Zhitong Finance APP, ESSEX BIO-TECH announced that its indirectly wholly-owned subsidiary, Zhuhai ESSEX Bio-Pharmaceutical Co., Ltd., has obtained approval from the National Medical Products Administration to register and commercialize multi-dose Diquafosol Sodium Eye Drops in mainland China (approved product). The approved product is a multi-dose eye drop containing 3% (5ml: 150mg) Diquafosol Sodium, suitable for the treatment of dry eye syndrome (such as conjunctival epithelial damage and tear abnormalities)

    Zhitong·
    HK
    01061
    -2.21%
    Zhitong·
    HK
    01061
    -2.21%

    Understanding the Market | ESSEX BIO-TECH surged nearly 16% during the session, rising over 60% in the past month as Bevacizumab reached the primary clinical endpoint in Phase III

    ESSEX BIO-TECH's stock price rose nearly 16% during the session, with a cumulative increase of over 60% since March 27. As of the time of writing, the stock price is up 11.52%, at HKD 4.55, with a trading volume of HKD 14.6944 million. The company's HLX04-O (Bevacizumab) has shown efficacy comparable to Ranibizumab and good safety in Phase III clinical trials in Chinese patients. An international multicenter Phase III clinical study is ongoing, with a new drug application expected to be submitted in 2025

    Zhitong·
    HK
    01061
    -2.21%
    Zhitong·
    HK
    01061
    -2.21%

    ESSEX BIO-TECH: The Phase III clinical study results of the anti-VEGF ophthalmic injection biologic for the treatment of wet AMD in Chinese patients have reached the primary endpoint

    ESSEX BIO-TECH announced that its anti-VEGF ophthalmic injection biologic HLX04-O for the treatment of wet AMD has achieved its primary endpoint in the Phase III clinical study AURA-1. The results showed that the improvement in best-corrected visual acuity at week 48 with HLX04-O was comparable to that of Ranibizumab, and both had similar safety profiles. HLX04-O is a new ophthalmic formulation optimized based on Hanbeitai®, and the international multicenter Phase III clinical study AURA-2 is currently underway, expected to be completed in 2025

    Zhitong·
    HK
    01061
    -2.21%
    Zhitong·
    HK
    01061
    -2.21%
    © 2025 Longbridge｜Disclaimer